Compare LMAT & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | ADNT |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2006 | N/A |
| Metric | LMAT | ADNT |
|---|---|---|
| Price | $83.30 | $19.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 10 |
| Target Price | ★ $101.83 | $21.90 |
| AVG Volume (30 Days) | 177.1K | ★ 1.1M |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 27.40 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | $240,866,000.00 | ★ $14,535,000,000.00 |
| Revenue This Year | $15.17 | $1.49 |
| Revenue Next Year | $9.07 | $2.15 |
| P/E Ratio | $35.31 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $71.42 | $10.04 |
| 52 Week High | $105.55 | $26.16 |
| Indicator | LMAT | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 50.85 |
| Support Level | $79.40 | $18.98 |
| Resistance Level | $86.00 | $19.87 |
| Average True Range (ATR) | 2.22 | 0.55 |
| MACD | -0.06 | 0.10 |
| Stochastic Oscillator | 45.64 | 66.67 |
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.